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two cases of IAH, which were successfully treated with steroid regimens 
administered at different doses and routes� The aim of this study is to 
evaluate pituitary mass lesions in patients receiving Ipilimumab for the 
treatment of advanced metastatic melanoma� Methods: Two cases, one 
male and one female, presenting to TTH were reviewed and their clinical 
progression assessed via radiological and biochemical results� Results: 
IAH was a rare side effect observed in both cases, clinically manifesting as 
extreme lethargy, and central hypothyroidism� Magnetic resonant imaging 
of the brain demonstrated a pituitary mass with stalk thickening� Patients 
successfully responded to high-dose steroids, one on oral prednisolone alone 
and the other with an additional course of intravenous methyprednisolone� 
Complete radiological resolution of the pituitary mass occurred after six 
weeks, although both required ongoing hormone replacement thereafter� 
Unfortunately, one of the patients succumbed to her disease shortly after 
completing this treatment; the other remains stable on ongoing thyroxine 
replacement� Conclusion: IAH is a new and defined clinical entity occurring 
as a side effect of Ipilimumab therapy� However, it is successfully treatable 
with high-dose steroids, producing both resolution of pituitary masses and 
improvement in pituitary function�
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Background/Aims: Recent human genetic, proteomics and metabolomics 
studies suggest that abnormal glucose and energy metabolism may underlie 
the pathophysiology of a number of neuropsychiatric disorders, including 
schizophrenia and autism. However, the effects of specific disruption of 
glucose metabolism on behaviour have not been elucidated� This study 
aims to examine the effect of pharmacological disruption of glucose 
metabolism on behaviours relevant to schizophrenia and autism in mice� 
Methods: Three key enzymatic steps of glycolysis were pharmacologically 
targeted by acute systemic administration of specific inhibitors, including 
2-deoxy-D-glucose (2DG, inhibitor of hexokinase), iodoacetate (inhibitor 
of glyceraldehyde-3-phosphate dehydrogenase, G3PDH) and oligomycin 
(inhibitor of ATP synthase)� The resultant behavioural endophenotype 
(alterations in psychomotor activity, social behaviour, working and reference 
memory) was investigated by using a battery of tests, including open field, 
social interaction test, and the working and reference memory versions 
of the Y-maze� Psychomotor activity was investigated both in novel and 
familiar environment to assess the potential interaction between stress and 
glucose metabolism� Results: Inhibition of hexokinase dose-dependently 
alters psychomotor activity and social behaviour while working memory 
remains intact. Inhibition of G3PDH and ATP synthase may result in specific 
alterations in behavioural endophenotypes of schizophrenia and autism� 
Conclusion: Preliminary results show that pharmacological inhibition of 
glycolysis results in abnormal behaviour suggesting that the perturbation 
of this metabolic pathway may play a causal role in the pathophysiology of 
neuropsychiatric disorders�
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Background/Aims: Many women giving birth in health facilities now labour 
in bed� However, there is no evidence that this activity is associated with any 
advantage for women or their babies� The aim of this systematic review and 
meta-analysis was to assess the effects of encouraging women to assume 
different upright positions versus recumbent positions during first stage of 
labour, on the duration of labour, type of birth and other important outcomes 
for mothers and babies� Methods: This review included randomised 
and quasi-randomised trials� The methods used for data collection, 
assessment of study quality and analysis of the results are described in 
the Cochrane Handbook for Systematic Reviews of Interventions� Results: 
The methodological quality of the 25 included trials (5218 women) was 
variable� However, meta-analysis demonstrated clear evidence that upright 
positions in the first stage of labour reduced the duration of labour, the risk 
of caesarean birth and the need for epidural� Conclusion: Based on these 
findings, we recommend that women in low-risk labour should be informed 
of the benefits of using upright positions during the first stage of labour. 
There is little doubt that women should adopt positions which give them the 
greatest comfort, control and benefit during labour. More research of better 
quality is needed to validate these results for all women in labour�
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Background/Aims: To compare the management of pelvic inflammatory 
disease (PID) at the Townsville Sexual Health Services (TNSHS) with the 
Queensland Sexual Health Clinical Management Guidelines (QSHCMG), 
and identify areas of discrepancy� Methods: A retrospective chart audit of 
patients diagnosed with PID between January 2012 and December 2013 
was conducted� Information from patient charts on the diagnostic criteria, 
investigations performed and management was retrieved and compared 
with the QSHCMG� Results: A total of 47 charts was identified with patient 
age range of 16-48 years.   There was insufficient documentation of many 
features that were deemed as risk factors for PID by the QSHCMG, such as 
having multiple partners, concurrent bacterial vaginosis, previous sexually 
transmitted disease, vaginal douching, post-partum endometriosis and 
recent uterine instrumentation� Minimal diagnostic criteria were met by 37 
(79%) patients� Documentation of investigations and management plan was 
complete in all patients� The antibiotic regimen prescribed (ceftriaxone 500 
mg IMI stat, metronidazole 400 mg BD for two weeks and azithromycin 1 g 
stat (plus repeat in one week) matched that in the QSHCMG in all patients� 
Symptom improvement was documented in 33 of 40 patients (83%)�   Seven 
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patients (15%) were lost to follow-up� Conclusion: Improvements could 
be made in the documentation of important parts of the history and clinical 
features that identify those patients diagnosed with PID�
Di-peptidyl peptidase IV Inhibitors: 
a new horizon in management of 
atherosclerosis: a review
Tejas P. Singh,1 Venkat N. Vangaveti1 and Usman H. Malabu1,2
1Translational Research on Endocrinology and Diabetes (TREAD), College of Medicine and 
Dentistry, James Cook University, Queensland
2Department of Endocrinology and Diabetes, The Townsville Hospital, Townsville, Queensland
Background/Aims: Dipeptidyl peptidase-IV (DPP-4) inhibitors are a relatively 
new class of anti-diabetic drugs that have therapeutic potential for management 
of atherosclerosis� Of the numerous DPP4-inhibitors in clinical practice, no 
studies have been conducted to compare their anti-atherosclerotic effects 
despite growing evidence of their usefulness in the high-risk population� 
The aim of the study is to evaluate and grade the anti-atherothrombotic 
effects of DPP-4 inhibitors in subjects with atherosclerosis� Methods: A 
literature search was conducted on MEDLINE and the Cochrane Library 
using the terms ‘DPP-4 Inhibitors’, ‘atherosclerosis’, ‘GLP’, ‘inflammation’, 
‘cytokines’, ‘stroke’, ‘ischaemic heart disease’, ‘hypertension’ and ‘peripheral 
vascular disease’� A mathematical model devised by us was used to 
derive and compare the anti-inflammatory effects of the DPP-4 inhibitors 
using protective score (PS)� Data were analysed for alogliptin, linagliptin, 
saxagliptin, sitagliptin, and vildagliptin� Results: Sixty-two published studies 
collected in the search were assessed for relevance to this study� Sitagliptin 
had the highest PS (n=5) while Linagliptin and Saxagliptin yielded the lowest 
PS (n=1)� This comparison and scoring system was limited to the data 
collected, which did not investigate all athero-thrombotic factors selected in 
this study� Conclusion: The findings reflected superiority of sitagliptin over 
the other DPP-4 inhibitors in the management of atherosclerosis� Further 
investigations are required to establish specific inflammatory cytokines 
influenced by the DPP-4 inhibitors and to elucidate their clinical application 
in atherothrombotic disease� 
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Background/Aims: Dipeptidyl peptidase-IV (DPP-4) inhibitors are a 
relatively new class of anti-diabetic drugs that have therapeutic potential for 
management of hypercholesterolemia� Of the numerous DPP4-inhibitors 
in clinical practice, no systematic review has been conducted to compare 
their anti-hypercholesterolemic effect, despite growing evidence of their 
usefulness in the high risk population� Methods: A systematic review of 
existing literature investigating cholesterol-lowering effects of DPP4 inhibitors 
was conducted� Published data on DDP-4 inhibitors use for more than six 
months in hypercholesterolemic subjects were sought from MEDLINE, 
PubMed and Google Scholar search of English language literature from 1994 
to 2014 using the key words: ‘DPP-4 inhibitors’, ‘hypercholesterolemia’ 
‘dyslipidemia’ and ‘hyperlipidemia’� Results: A total of six full-text published 
studies conducted worldwide were included in this systematic review, 
comprising a total of 3968 subjects� Anti-hypercholesterolemic effects range 
between 13�3% reduction in total cholesterol by sitagliptin and vildagliptin, to 
no effect by linagliptin�  Conversely, saxagliptin demonstrated modest anti-
hypercholesterolemic effect� Conclusions: These findings reflected potential 
benefit of using DPP-4 inhibitors in the management of hypercholesterolemia 
particularly in subjects with diabetes� Further investigations are required to 
establish specific anti-hypercholesterolemic effects of DPP-4 inhibitors and 
to elucidate their clinical application in addition to its established anti-diabetic 
effects�
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Background/Aims: Marine microalgae contain a large variety of bioactive 
substances that can be harnessed for their therapeutic potentials, including 
polyunsaturated fatty acids (PUFA), sterols, carotenoids, pigments, proteins 
and vitamins� A possible implication of these bioactive molecules is to control 
inflammatory processes. Stress-related mental illnesses, such as depression, 
have been associated with systemic inflammatory processes. However, the 
effects of microalgal diet on behaviour have not been investigated� The aim of 
this study is to examine the effect of microalgal diet on the depression-related 
behavioural consequences of chronic social defeat (CSD) in mice� Methods: 
From the age of 21 days for 11 weeks mice were fed with either (1) control 
normal mouse chow, or  mouse chow containing (2) high concentration of 
saturated fats (high-fat ‘Western diet’; HFD), or (3) microalgal biomass with 
high concentration of PUFAs (including docosahexanoic acid, DHA), or (4) 
de-fatted algal biomass (ALG)� Mice were then either subjected to CSD or 
remained undisturbed� Psychomotor activity, anxiety-like behaviour and 
cognitive functions were measured using open-field, elevated plus maze, 
Y-maze and novel object recognition, respectively, taking advantage of a 
behavioural recognition software, TopScanLite (CleverSystem)� Results: 
CSD induced social avoidance in HFD and DHA mice� ALG feeding prevented 
psychomotor retardation and cognitive impairments induced by CSD but 
HFD and DHA resulted in a worsening of the behavioural consequences 
of CSD� Conclusion: Our preliminary results show that certain bioactive 
compounds contained in the de-fatted microalgae may have beneficial effects 
in preventing adverse behavioural consequences of chronic psychosocial 
stress in mice and high DHA concentrations should be used with caution�
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Background/Aims: Many emergency departments (EDs) state-wide use 
emergency pack (EP) systems for discharging patients outside of pharmacy 
hours� Patients receive the EP without counselling from a pharmacist� Not all 
medications have consumer medication information (CMI) pre-supplied� The 
Pharmacy Board of Australia, Pharmaceutical Society of Australia and the 
Society of Hospital Pharmacists Australia all advocate for the provision of CMI� 
Their use is well documented to improve safety, compliance and continuity 
of care� Under these circumstances where a pharmacist is unavailable, a CMI 
is highly recommended� The aim of this study is to review and improve the 
current EP processes across the health district to meet standards held by our 
professional governing bodies� Methods: EP stock holding of four hospitals 
within our health service district was reviewed to determine the percentage 
of EPs that contained CMIs� The current procedure was changed so that 
